Summit Therapeutics PLC (LON:SUMM) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $23.90. Summit Therapeutics shares last traded at $23.90, with a volume of 7,937 shares changing hands.
The business’s 50-day simple moving average is GBX 24.10.
Summit Therapeutics (LON:SUMM) last issued its quarterly earnings data on Wednesday, June 12th. The company reported GBX (3) (($0.04)) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (4) (($0.05)) by GBX 1 ($0.01). As a group, equities research analysts anticipate that Summit Therapeutics PLC will post -33.4000021 EPS for the current year.
Summit Therapeutics Company Profile (LON:SUMM)
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.